Chapter 66: Drugs for Peptic Ulcer Disease

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replace the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, usually when you are studying for clinicals or prepping for your board exams, you kind of expect this, well, this comforting level of precision in medicine.

Right, you're binary answers.

Exactly.

Like a patient comes in with a broken bone, the x -ray shows this jagged white line and, you know, the treatment plan is just obvious.

You cast it.

Yeah, it's a structural problem.

So you just fix the structure.

Right.

It's visible.

But then you step into the world of gastroenterology, specifically peptic ulcer disease.

And suddenly that reliable diagnostic machinery just, it feels totally inadequate.

It really did.

I mean, for a very long time, at the stomach was essentially looking into diagnostic muddy waters.

Peptic ulcer disease, or PUD, was considered this chronic, endlessly relapsing disorder.

Yeah.

And the clinical consensus back then was basically just that we had no known cure, right?

Exactly.

Therapy was almost entirely focused on promoting temporary healing, you know, with antacids and bland diets.

But the ulcer almost always came back.

And that is a massive public health issue because, well, PUD affects about 10 % of Americans at some point in their lives.

Yeah.

We were talking about 26 million people suffering from ulcers every single year.

It's huge.

But then, and this is the crazy part, in the mid 1990s, the medical world experienced this massive paradigm shift.

Two Australian scientists, Barry J.

Marshall and J.

Robin Warren, they essentially turned gastroenterology upside down.

They absolutely did.

They proved that most of these ulcers were actually caused by a bacterial infection.

Which is just wild to think about now.

It is.

And that discovery fundamentally changed how clinicians approach the disease today.

I mean, we moved from merely managing a chronic condition to actively eradicating an infectious agent.

Right.

A leap from just symptom control to an actual literal cure, which brings us to our mission for today.

Welcome to the deep dive.

Glad to be here to break this down.

Yeah.

So whether you are an advanced practice nursing student or like a PA student prepping for your exams right now, think of this as your focused one -on -one tutoring session.

We are covering chapter 66 of Lens Pharmacotherapeutics, Drugs for Peptic Ulcer Disease.

And we are going to break down this chapter exactly as it unfolds in the text.

Our blueprint today is highly logical.

I love a good blueprint.

Where do we start?

Well, we'll start with the underlying path of physiology.

You know, to really understand the environment of the stomach.

From there,

those disease mechanics are going to dictate our therapeutic goals.

Then we'll walk through the specific drug classes.

So antibiotics, H2 receptor antagonists, proton pump inhibitors, mucosal protectants, and antacids.

We're covering it all.

Every bit of it.

We will examine their mechanisms of action, pharmacokinetics, adverse effects, and the critical patient education points.

Because the ultimate goal here is to show you how rational drug selection leads to safe, patient -centered outcomes.

So, okay, let's unpack this.

Starting with the path of physiology.

Because, I mean, before we can treat an ulcer, we really have to understand why the stomach begins digesting itself in the first place.

Right.

And it really comes down to a delicate

microscopic balance.

Picture a scale.

Okay, I'm picturing a scale.

On one side of that scale, you have mucosal defensive factors.

These elements serve the physiological role of protecting the stomach and the duodenum from self -digestion.

So they're the good guys.

Exactly.

The major players here are mucus, which forms a physical barrier,

and bicarbonate.

Bicarbonate neutralizes any acid that actually manages to penetrate that mucus.

Okay, so mucus and bicarb.

What else?

You also have adequate blood flow.

This is vital because it literally sweeps away any hydrogen ions that breach the mucosal layer.

And finally, you have prostaglandins.

Prostaglandins.

I always see those come up.

Yeah, they are the foundational regulators here.

They absolutely stimulate the that mucous and bicarbonate, and they promote the vasodilation that maintains that crucial blood flow.

You know, I always like to think of the GI tract like a medieval castle under siege.

Oh, I like that.

Yeah, so your defensive factors, those are the fortifications.

The mucus layer and the bicarbonate, they act as your physical stone wall and the moat surrounding it.

Right, keeping the invaders out.

Exactly.

And the prostaglandins are the crucial supply lines.

They're bringing in reinforcements and keeping the guards fed.

But on the other side of that scale, you have the aggressive factors.

The elements actively trying to cause injury.

Right.

So we're looking at helicobacter pylori, non -steroidal anti -inflammatory drugs.

So NSAIs, gastric acid, pepsin, and smoking.

And when the defenses are intact, those aggressive factors are kept at bay.

But when that scale tips, either because defenses are weakened, or the aggressive factors become overwhelmingly strong,

well, the acid and pepsin eat into the mucosal wall, and that creates an ulcer.

And sticking with that castle analogy for a second,

NSAIs essentially cut off those supply lines, right, by inhibiting the production of prostaglandins.

Exactly.

Without prostaglandins, the wall crumbles.

And H.

pylori is like the sneaky invading force that manages to scale the walls and hide right inside the defenses.

The text actually notes that it's a gram -negative bacillus.

It takes up residence in this tiny microscopic space between the epithelial cells and the protective mucous barrier.

Yeah.

And by hiding in that specific pocket, it escapes destruction by the stomach's own acid and pepsin.

It's so smart.

But the textbook highlights this wild paradox about H.

pylori.

Like, about half of the entire world's population is infected with it.

That's right.

50%.

Yet most infected people never develop symptomatic PUD.

Only about 10 % do.

So, I mean, we really have to ask, what makes it so dangerous for that 10 %?

That's a great question.

While the exact mechanism isn't completely mapped out, we do know H.

pylori produces an enzyme called urease.

Urease.

Right.

Urease concludes urea in the gastric juice into carbon dioxide and ammonia.

And ammonia is highly alkaline.

So the bacteria essentially creates this little alkaline bubble around itself to survive the harsh acid.

Wow.

So it builds its own little shield.

Exactly.

Unfortunately, ammonia is also potentially toxic to the gastric mucosa.

Plus, the bacteria itself degrades the protective mucous layer and provokes a really damaging local inflammatory response.

Which tips the scale.

Yep.

And here is a major clinical priority for your practice.

H.

pylori is classified as a type 1 carcinogen.

A type 1 carcinogen.

I mean, labeling it that really shifts the perspective, doesn't it?

We aren't just treating localized stomach pain here.

We are actively preventing cancer.

Absolutely.

It is strongly linked to gastric cancer and mucosa associated lymphoid tissue or malt lymphomas.

Right.

The clinical proof of this is that eradicating the bacteria produces actual tumor regression in like 60 to 90 % of localized malt lymphoma cases.

That is incredible.

Just curing the infection shrinks the tumor.

It's amazing.

So beyond H.

pylori and NSAIDs, the text mentions a few other aggressors that can tip that scale.

There's Zollinger -Ellison syndrome, which is rare.

Very rare.

It accounts for only about 0 .1 % in duodenal ulcers.

Right.

It's a gastrin -secreting tumor that causes this massive, overwhelming acid hypersecretion.

It just totally overwhelms the mucosal defenses.

And then we also have to account for smoking.

Yes.

Smoking is a major aggressive factor.

It significantly delays ulcer healing and increases the risk of recurrence.

How does it do that?

Exactly.

It reduces bicarbonate secretion and accelerates gastric emptying, so it's basically delivering more acid to the duodenum faster.

Not a good combination.

Not at all.

And knowing all of this pathophysiology directly dictates our therapeutic strategy.

Yeah.

Because H.

pylori is the primary culprit for most ulcers.

Non -antibiotic therapies like antacids or acid reducers used alone, they're insufficient.

They just temporarily patch things up.

Exactly.

They only heal the ulcer temporarily.

Yeah.

Because they do not eradicate the bacteria, the relapse rate remains incredibly high.

To cure an H.

pylori -associated ulcer, antibiotics are mandatory.

Okay.

So if antibiotics are the definitive cure, I can see a lot of students wondering why do the clinical guidelines require patients to take up to 12 pills a day?

Like, combining multiple antibiotics with acid reducers, why not just prescribe a standard short course of a single antibiotic and send them home?

Oh, because H.

pylori is incredibly resilient.

Isolated antibiotic resistance is a massive hurdle in gastroenterology right now.

Right.

The resistance rates are going up everywhere.

Yeah.

To address this, the American College of Gastroenterology updated their clinical guidelines back in 2017.

To prevent resistance, clinicians are required to prescribe at least two and preferably three antibiotics simultaneously.

Wow.

Up to three at once.

Yes.

Combined with an anti -secretory agent, like a proton pump inhibitor or an H2 receptor antagonist.

Furthermore, this whole regimen must be taken for a full 10 to 14 days.

That's a heavy pill burden for a patient.

So if you are looking at that guideline as a prescriber, deciding which combination to use depends largely on your local resistance rates, right?

Exactly.

In areas where resistance to the antibiotic clarithromycin is low meaning below 20%, the preferred route is clarithromycin -based triple therapy.

Okay.

And what's in that triple therapy?

That consists of a standard dose PPI, clarithromycin, and amoxicillin.

Let's break down the mechanisms there.

How does clarithromycin work?

Clarithromycin inhibits bacterial protein synthesis.

It effectively stops the bacteria from multiplying.

Amoxicillin, on the other hand, disrupts the bacterial cell wall, causing it to rupture.

But there is a very specific physiological reason we combine amoxicillin with proton pump inhibitor, right?

Yes.

Amoxicillin has its highest antibacterial activity at a neutral pH.

It really only works well on actively dividing bacteria and H.

pylori doesn't divide well in a highly acidic environment.

Right.

So by using a PPI to aggressively suppress stomach acid, we create this neutral environment where the amoxicillin can do its job far more effectively.

That synergy is incredible.

That's the cornerstone of the triple therapy.

However, if a clinician is practicing in an area with high clarithromycin resistance, they must shift to a bismuth -based quadruple therapy.

Right, the quadruple therapy.

That regiment includes a PPI, bismuth,

subsalicylate, metrodidazole, and tetracycline.

You know, I always thought of bismuth as just like the pink liquid you take for a minor upset stomach.

A lot of people do.

But the text shows it acts as a physical disruptor to the bacterial cell wall.

It prevents H.

pylori from adhering to the gastric surface.

But there is a vital patient education point here for your clinicals.

You absolutely must warn your patients that bismuth compounds can impart a harmless black coloration to their tongue and their stool.

This is such an important point.

If you don't forewarn them, a patient will look in the toilet, see black, turry stool, and they'll assume it is malena, you know, the clinical sign of an upper GI bleed.

And they end up in the emergency room in an absolute panic.

Setting that expectation up front prevents so many unnecessary hospital visits.

Now looking at the rest of the quadruple therapy, we have tetracycline, which inhibits protein synthesis.

And the primary safety alert there.

The big safety alert for tetracycline is that it stains developing teeth, meaning it is strictly contraindicated in pregnant patients and young children.

Okay, got it.

And if you are studying for your boards right now, put a massive star next to this final antibiotic, metronidazole.

There is a massive safety priority here regarding alcohol consumption.

Yes, zero alcohol.

None.

Zero alcohol can be consumed while on this drug.

If a patient takes metronidazole and consumes even a small amount of alcohol, they will experience a severe disulfiram -like reaction.

What does that actually look like for the patient?

It involves extreme nausea, violent vomiting, severe headache, and flushing.

It is an intensely unpleasant and physically dangerous physiological response.

Definitely something to emphasize during patient education.

Okay, so we use this heavy artillery of antibiotics to eradicate the bacterial invader, but we still have an active painful ulcer crater sitting in the stomach lining.

Right, the damage is already done.

So we need to turn down the volume on the stomach acid to relieve the pain and allow that crater to physically heal.

That leads us to the anti -secretory agents, starting with the histamine 2 receptor antagonists, or H2RAs.

Our prototype drug in this class is cimetidine.

Right, and to understand how cimetidine works, we have to look at the cellular level of the stomach.

There are three endogenous stimulators of gastric acid,

acetylcholine, histamine, and gastrin.

Okay, acetylcholine, histamine, and gastrin.

Yes.

Histamine acts specifically at the H2 receptors, which are located on the parietal cells of the stomach lining.

By selectively blocking those H2 receptors, cimetidine significantly reduces both the total volume of gastric juice secreted and its overall hydrogen ion concentration.

So it just turns the volume way down.

From a pharmacokinetic standpoint, it's given orally.

Interestingly, the text mentions that taking it with food slows down its absorption slightly.

It does, but that actually prolongs its beneficial effects.

It provides longer acid suppression overall.

Oh, that's a nice trade -off.

It is primarily eliminated through the kidneys, so if you have a patient with renal impairment, their dose must be reduced to prevent the drug from accumulating to toxic levels.

Exactly.

And cimetidine is also a highly tested drug on clinical exams because of its unique adverse effects and drug interactions.

Yeah, let's get into those because they are kind of wild.

First, it binds to androgen receptors in the body, producing an accidental hormonal blockade.

Wow.

Yeah.

In some patients, this can cause reversible gynecomastia, reduced libido, and impotence.

And the text notes it can also cross the blood -brain barrier.

It can.

Now, it does so with difficulty in healthy younger individuals, but older adults, especially those with renal or hepatic impairment where the drug accumulates, they are highly susceptible.

So what happens if it crosses the barrier in an older adult?

It can cause central nervous system effects, ranging from confusion and hallucinations to severe CNS depression or excitation.

That's terrifying to see if you don't know it's just their ulcer medication.

But the most critical safety issue in clinical practice is that cimetidine acts as a strong hepatic enzyme inhibitor.

Yes, it actively inhibits the liver's cytochrome P450 system.

And when this metabolic pathway is slowed down, the blood levels of other drugs the patient is taking begin to rise.

Exactly.

And this becomes a severe danger when dealing with narrow margin drugs like warfarin, phenytoin, and theophyllin.

Because there's so little room for error with those.

Right.

If a patient is stable on these medications and you introduce cimetidine, their levels will spike right into the toxic range.

The doses of those narrow margin drugs must be proactively reduced.

Good to know.

Okay, so if H2RAs turn down the volume of the acid by blocking one specific receptor, the next class of drugs unplugs the speaker entirely.

The proton pump inhibitors or PPIs.

Yes, PPIs are the most effective drugs we have for acid suppression.

Our prototype here is omeprazole.

Omeprazole essentially blocks the final common pathway of gastric acid production.

It is formulated as a prodrug, meaning it undergoes conversion to its active form only once it is inside the acidic environment of the cells.

Right.

Once activated, it irreversibly inhibits the H plus K plus natch ATPase enzyme.

That enzyme is the literal proton pump that exchanges potassium ions for hydrogen ions, pushing acid into the stomach.

But the textbook presents this fascinating kinetic puzzle here.

It states that omeprazole has a plasma half -life of only one hour.

Yes.

Yet the acid suppression lasts for days.

How does a drug that clears the bloodstream in 60 minutes continue working for almost a week?

The key is that word irreversible.

The drug enters the parietal cell, binds to the proton pump permanently, literally breaking it, and then the actual drug is metabolized and eliminated an hour later.

So the drug is gone, but the damage to the pump is done.

Exactly.

The pump remains broken.

The body is forced to physically synthesize brand new enzymes to start producing acid again, a physiological process that takes three to five days.

That is brilliant.

The pharmaceutical engineering behind the pill itself is also quite remarkable.

Omeprazole is acid labile, meaning the harsh stomach acid would normally just destroy the medication before it ever had a chance to work.

Right.

So how do they fix that?

To circumvent this, it's manufactured as a capsule containing enteric -coated granules.

When a patient swallows it, the outer capsule dissolves in the stomach, but those specialized granules survive the acid bath.

They're armored.

Yeah.

They only dissolve and release the active drug once they reach the alkaline environment of the duodenum.

That's where the drug can be safely absorbed into the bloodstream.

It is a brilliantly designed and highly effective system.

However, that efficacy has led to significant overuse in clinical settings.

Oh yeah.

Particularly in hospitals with something called stress ulcer prophylaxis.

This is a massive safety priority.

We see the stress ulcer myth constantly.

A patient gets admitted to a general medical floor for something completely unrelated,

like pneumonia,

and suddenly they are prescribed a daily PPI just because they're in a hospital bed.

And the clinical guidelines aggressively push back against this.

General medical and surgical patients do not routinely need stress ulcer prophylaxis.

So who actually needs it?

The indications are very specific.

It is only meant for patients in the intensive care unit who have specific severe risk factors.

Things like multiple trauma, spinal cord injuries, or those requiring prolonged mechanical ventilation lasting more than 48 hours.

Okay.

So ICU level only.

Right.

Using PPIs unnecessarily outside of these parameters exposes the patient to adverse effects and complex drug interactions for absolutely zero clinical benefit.

And speaking of complex interactions, if you are a student, you must understand the plebex dilemma.

We are talking about the interaction between omeprazole and

Yes.

Let's trace the physiological logic here carefully.

Clopidogrel is a vital antiplatelet drug used to prevent catastrophic blood clots in cardiac patients.

Right.

But because it stops platelets from clumping, it inherently causes a systemic risk of bleeding, including gastrointestinal bleeding.

So logically, a well -meaning clinician might think, I should prescribe a PPI to protect their stomach lining and prevent a GI bleed.

But the cellular conflict is where the danger lies.

Clopidogrel is a pro drug.

It relies on a specific liver enzyme, CYP2C19, to convert it into its active clot blocking form.

And guess what?

Omeprazole happens to be a strong inhibitor of that exact same enzyme, CYP2C19.

Oh, wow.

So if you prescribe them together, the PPI protects the stomach, but it prevents the clopidogrel from activating.

You're leaving the patient at an unacceptably high risk for a heart attack or The consensus framework from cardiology and gastroenterology organizations relies on strict risk stratification.

If the patient has major documented risk factors for a GI bleed, such as advanced age or concurrent heavy NSAI use, the benefit of preventing a catastrophic stomach bleed outweighs the slight reduction in the antiplatelet effect, and you combine them cautiously.

Okay, but what if they don't have those risk factors?

If they do not have significant GI bleed risk factors, you do not prescribe the PPI.

Doing so simply neutralizes their heart medication.

We also have to consider the long -term adverse effects of PPIs.

Because acid is required to properly absorb dietary calcium, long -term acid suppression leads to decreased calcium absorption.

Which increases the risk of osteoporosis and bone fractures.

Exactly.

Patients also face the risk of rebound acid hypersecretion if the drug is stopped abruptly, so they must be tapered off

Furthermore, profoundly altering the normal acidic environment of the gut changes the local flora, and that can allow severe infections like difficult diarrhea to take hold.

So what's the golden rule for PPIs?

The overarching clinical rule is always to prescribe the lowest effective dose for the shortest possible duration.

Lowest dose, shortest time.

Got it.

So we have explored killing the bacteria and shutting down acid production.

But what if a patient has an active ulcer and we simply need to physically shield the crater?

Or maybe neutralize the acid that is already sloshing around.

That brings us to our final drug classes, nucosal protectants and antacids.

Starting with sucralpate.

Right.

Sucralpate is our primary nucosal protectant.

The mechanism here is fascinating.

It functions almost like a liquid band -aid.

Under mildly acidic conditions,

specifically when the gastric pH is below 4 sucralpate, undergoes this chemical polymerization reaction.

So it changes state.

Yeah.

It transforms from a standard medication into this viscid, incredibly sticky gel, and it physically adheres to the protein crater of the ulcer.

It creates this robust barrier against hydrogen ions and pepsin that lasts for up to six hours.

And it boasts a highly favorable safety profile because it acts almost entirely locally.

Only about three to five percent of the drug is absorbed systemically.

But there is a catch with the timing, right?

Yes.

The safety priority revolves around administration timing.

Because it forms such a thick, sticky coating in the gut, it can physically block the absorption of other critical narrow margin drugs.

Drugs like phenytoin and warfarin.

So you have to space them out.

Exactly.

Planitians must ensure sucralpate is administered at least two hours apart from these medications.

Moving on, the text discusses a prostaglandin analog called mesoprostol.

This requires a very serious clinical approach because it carries a prominent black box warning.

Yes, it does.

First, let's understand its purpose.

Mesoprostol is designed to replace the endogenous prostaglandins that are aggressively depleted when a patient is taking long -term high -dose antisides for conditions like rheumatoid arthritis.

So it steps in to suppress acid, promote mucus and bicarbonate secretion, and maintain mucosal blood flow.

Exactly.

The black box warning, however, is absolute.

Mesoprostol is strictly contraindicated during pregnancy.

Because it's a prostaglandin analog.

Right.

It actively stimulates uterine contractions.

If taken during pregnancy, it can cause partial or complete expulsion of the developing fetus.

And the clinical protocol for prescribing this is incredibly strict.

If you are treating a biological female of childbearing age, they must have a documented negative serum pregnancy test within two weeks of starting therapy.

Yes.

They are required to use highly effective birth control and they must receive both oral and written warnings about the drug's dangers.

And on top of that, they can only initiate the medication on the second or third day of their normal menstrual cycle to absolutely ensure they are not pregnant when the first dose is taken.

It's a very strict protocol.

Finally, we round out our pharmacological toolkit with standard antacids.

It's classic.

Classics.

These are simply alkaline compounds that directly interact with and neutralize the stomach acid that has already been secreted into the lumen.

When you look at the comparison table in the text, selecting an antacid basically comes down to managing the patient's bowel side effects.

It really does.

Aluminum hydroxide is highly effective but tends to cause severe constipation.

Right.

And magnesium hydroxide, which is commonly known as milk of magnesium, works well but causes diarrhea.

Therefore, clinicians will frequently combine the two in a single liquid formulation.

That way, the constipating effects of the aluminum balance out the diarrheal effects of the magnesium.

That's pretty clever.

But there is a vital clinical note here, right?

Many of these over -the -counter antacid compounds contain substantial amounts of sodium.

Yes.

If you are treating a patient with hypertension or heart failure, you must actively warn them against sodium loading with antacids.

It can severely exacerbate their cardiovascular condition.

Okay.

Let's tie all of these pharmacological mechanisms back to the specific patient sitting in the exam room.

The chapter includes a really helpful lifespan table detailing how age impacts these treatment choices.

Right.

Let's walk through that.

For infants and children, PPIs and H2RAs are actually quite safe.

They are simply scaled down to proportionally smaller doses.

And what about for breastfeeding patients?

Medications like omeprazole are not predicted to cause any adverse effects in the nursing infant.

But older adults, that's where we need to be careful, right?

Older adults demand heightened caution.

Due to the significantly increased risk of osteoporosis -related fractures, the potential for severe medication interactions via hepatic enzyme inhibition, and vitamin deficiencies caused by altering stomach acid,

well, older adults require a very clear, heavily documented indication before being placed on a PPI or an H2RA.

So a clinician should never just leave an older adult on these medications indefinitely by default.

Exactly.

Never by default.

So what does this all mean for you as a future clinician?

We've covered a massive amount of ground today from the fortifications of the GI mucosa and the synergy of antibiotic combinations right through to the precise engineering of an enteric -coded prodrug.

We really went through it all.

But there is a final, broader thought I want to leave you with, building on the paradox we discussed earlier.

Consider the fact that roughly half of the world's population carries H.

pylori in their stomach.

The textbook rightly focuses on how to eradicate it.

And for that 10 % who develop painful, dangerous ulcers or face cancer risks, eradication is absolutely necessary.

Right.

But what about the other 90 % who carry it silently?

It raises a fascinating question about the gut microbiome.

Since humans and H.

pylori have coexisted for tens of thousands of years, are we always fighting an invading pathogen?

Or are we sometimes inadvertently wiping out a coevolved resident that might be doing something we don't fully understand yet?

As personalized medicine evolves, our approach might shift from blanket eradication to actively managing the delicate, localized ecology of the human stomach.

It is a powerful reminder that in pharmacology, every intervention has an ecological consequence.

Rational drug selection, understanding the why and the how behind every single prescription is the most critical skill you can develop.

Thank you so much for tuning in to this deep dive.

From all of us on the Last Minute Lecture team, you've got this.

Good luck on your exams.

Good luck in your clinicals, and we'll catch you next time.